

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.	:	10/532,114	Confirmation No. :	9051
First Named Inventor	:	Francois Schutze		
Filed	:	June 23, 2006		
TC/A.U.	:	1614		
Examiner	:	Phyllis G. Spivack		
Docket No.	:	104006.B130119		
Customer No.	:	23911		
Title	:	PHARMACEUTICAL COMPOSITION COMBINING TENATOPRAZOLE AND A HISTAMINE H-2 RECEPTOR ANTAGONIST		

RESPONSE TO INTERVIEW SUMMARY

Mail Stop AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


In response to the Interview Summary mailed June 26, 2009, issued in connection with the above-referenced application, Applicants thank Examiners Spival and Marchel for the courtesy extended to Applicants' representative during the personal interview conducted on June 23, 2009, and submit the following comments:

During the interview, Examiners Spival and Marchel and the undersigned Applicants' representative discussed Claims 1-6 and 9-18 of the above-referenced application in light of prior art Brulls, M., U.S. Patent 6,730,685. As indicated in the Interview Summary, the possible filing of a declaration detailing unexpected results for the claimed combination was discussed, which would be filed with a Request for Continued Examination.

If there are any questions regarding this response or the application in general, a telephone call to the undersigned would be appreciated since this should expedite the prosecution of the application for all concerned.

If necessary to effect a timely response, this paper should be considered as a petition for an Extension of Time. Please charge any deficiency in fees or credit any overpayments to Deposit Account No. 05-1323 (Docket # 104006.B130119).

Respectfully submitted,



E. Joseph Gess
Registration No. 28,510

July 27, 2009

CROWELL & MORING LLP
Intellectual Property Group
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844
EJG/lk